抑制剂C | 121263-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苝醌类
• 中文名称: 抑制剂C
• 中文别名: 卡弗他丁C
• 英文名称: Calphostin C from Cladosporium cladosporioides
• 英文别名: calphostin C；calphostin-C；PKF-115-584；PFK115-584
• CAS: 121263-19-2
• 化学式: C₄₄H₃₈O₁₄
• 分子量: 790.777
• InChiKey: SRJYZPCBWDVSGO-UHFFFAOYSA-N

物化性质

• 沸点：
  1039.8±65.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：1 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  6.98
• 重原子数：
  58.0
• 可旋转键数：
  12.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  193.58
• 氢给体数：
  3.0
• 氢受体数：
  14.0

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  29209010
• 安全说明：
  S24/25

制备方法与用途

用途
这是一种高度特异性的蛋白激酶C（IC50=50 nM）抑制剂，需要通过光照激活。在较高浓度下（100 nM或更高），它已被证明能在体外抑制细胞增殖并诱导细胞凋亡。

文献信息

• Anti-CD70 combination therapy
  申请人：University of Bern

  公开号：US10391168B1

  公开（公告）日：2019-08-27

  Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.

  本文提供了使用WNT信号通路抑制剂和BCR-ABL1酪氨酸激酶抑制剂的治疗组合来治疗BCR-ABL1相关疾病（如慢性粒细胞白血病）的方法和组合物。
• Methods for treating diseases related to the wnt pathway
  申请人：Sandia Corporation

  公开号：US10624949B1

  公开（公告）日：2020-04-21

  The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.

  本发明涉及治疗疾病的方法，其中疾病是由 Wnt 信号通路失调引起的。在某些情况下，可以通过施用抑制 Wnt 通路的化合物来治疗疾病。在其他情况下，该方法可选地包括进行全基因组筛选，以确定导致疾病状态降低的一个或多个基因，然后确定这些基因参与Wnt信号通路。
• Prevention of Cell Proliferation by Inhibiting Myosin Light Chain Kinase
  申请人：de Lanerolle Primal

  公开号：US20080081078A1

  公开（公告）日：2008-04-03

  Methods of using compounds having certain inhibitory effect to treat cancer are disclosed. More specifically, methods of using myosin light chain kinase inhibitor (MLCK) to treat cancer are disclosed. MLCK inhibitors may cause reduction in MLC-P and induce apoptosis in neoplastic cells and prevent and or inhibit the tumor growth.
• Compositions and Methods for Promoting Epithelialization and Wound Closure
  申请人：Tomic-Canic Marjana

  公开号：US20120289463A1

  公开（公告）日：2012-11-15

  Compositions for antagonizing phosphorylation and subsequent degradation of glycogen synthase kinase 3 beta (GSK3β) in epidermal cells are disclosed. GSK3β phosphorylation antagonists include molecules that function to inhibit or reduce the binding activity or enzymatic activity of an upstream signaling molecule leading to GSK3β phosphorylation, or by downregulating the expression of one or more upstream signaling molecules involved in regulating GSK3β phosphorylation. Methods of using the GSK3β phosphorylation antagonists to inhibit or reduce the phosphorylation and degradation of GSK3β in epidermal cells are provided. The methods are useful to promote epithelialization and closure of wounds, such as chronic non-healing wounds.
• Improved Differentiation Method
  申请人：Koninklijke Nederlandse Akademie Van Wetenschappen

  公开号：US20210040454A1

  公开（公告）日：2021-02-11

  The invention relates to differentiation methods for progenitor cells, e.g. mammalian epithelial stem cells, differentiation media for use in said methods, organoids and cells obtainable by said methods and uses, including therapeutic uses, thereof.